These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18081131)

  • 1. Quantum-dot-based electrochemical immunoassay for high-throughput screening of the prostate-specific antigen.
    Wang J; Liu G; Wu H; Lin Y
    Small; 2008 Jan; 4(1):82-6. PubMed ID: 18081131
    [No Abstract]   [Full Text] [Related]  

  • 2. Disposable electrochemical immunosensor diagnosis device based on nanoparticle probe and immunochromatographic strip.
    Liu G; Lin YY; Wang J; Wu H; Wai CM; Lin Y
    Anal Chem; 2007 Oct; 79(20):7644-53. PubMed ID: 17877418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel electrochemical immunosensor based on colabeled silica nanoparticles for determination of total prostate specific antigen in human serum.
    Qu B; Chu X; Shen G; Yu R
    Talanta; 2008 Aug; 76(4):785-90. PubMed ID: 18656659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogold labeling-induced synergy effect for amplified photoelectrochemical immunoassay of prostate-specific antigen.
    Zhao WW; Dong XY; Wang J; Kong FY; Xu JJ; Chen HY
    Chem Commun (Camb); 2012 May; 48(43):5253-5. PubMed ID: 22362020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-based immobilization strategy for sensitive piezoelectric immunoassay of total prostate specific antigen.
    Ding Y; Lu H; Shi G; Liu J; Shen G; Yu R
    Biosens Bioelectron; 2008 Oct; 24(2):228-32. PubMed ID: 18468880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoasssay based on the antibody-conjugated PAMAM-dendrimer-gold quantum dot complex.
    Triulzi RC; Micic M; Giordani S; Serry M; Chiou WA; Leblanc RM
    Chem Commun (Camb); 2006 Dec; (48):5068-70. PubMed ID: 17146530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-gold quantum dot-PAMAM dendrimer complex as an immunoglobulin immunoassay.
    Triulzi RC; Micic M; Orbulescu J; Giordani S; Mueller B; Leblanc RM
    Analyst; 2008 May; 133(5):667-72. PubMed ID: 18427690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoassay by capillary electrophoresis with quantum dots.
    Feng HT; Law WS; Yu LJ; Li SF
    J Chromatogr A; 2007 Jul; 1156(1-2):75-9. PubMed ID: 17208246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labeless immunosensor assay for prostate specific antigen with picogram per milliliter limits of detection based upon an ac impedance protocol.
    Barton AC; Davis F; Higson SP
    Anal Chem; 2008 Aug; 80(16):6198-205. PubMed ID: 18642881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of prostate-specific antigen in prostate cancer.
    Liang SL
    MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantum dots-gold(III)-based indirect fluorescence immunoassay for high-throughput screening of APP.
    Sheng Z; Han H; Hu D; Liang J; He Q; Jin M; Zhou R; Chen H
    Chem Commun (Camb); 2009 May; (18):2559-61. PubMed ID: 19532889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 13. Mass screening for prostate cancer in Korea: a population based study.
    Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
    J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of quantum dot barcodes prepared using biological self-assembly to multiplexed immunoassays.
    Rauf S; Glidle A; Cooper JM
    Chem Commun (Camb); 2010 Apr; 46(16):2814-6. PubMed ID: 20369192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
    Kvåle R; Hernes E; Bray F
    Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate specific antigen screening and active surveillance in the elderly.
    Konety BR
    J Urol; 2009 Apr; 181(4):1534-5. PubMed ID: 19230925
    [No Abstract]   [Full Text] [Related]  

  • 20. Point-of-care fluorescence immunoassay for prostate specific antigen.
    Oh SW; Kim YM; Kim HJ; Kim SJ; Cho JS; Choi EY
    Clin Chim Acta; 2009 Aug; 406(1-2):18-22. PubMed ID: 19393638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.